Effect of modified immunotherapy with an allergen-pullulan conjugate in patients with Japanese cedar pollinosis

Allergology International

Volumn 50, Issue 1, 2001, Pages 43-55

  Pawankar, R ^a   Takizawa, R ^a   Goto, M ^a   Goto, Y ^a   Okuda, M ^a   Yamagishi, S ^a   Ohkubo, K ^a   Nonaka, M ^a   Ohtsuka, H ^a   Yagi, T ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Eosinophil; Immunotherapy; Japanese cedar pollinossis; Mast cell; Seasonal allergic rhinitis; Th1 cytokine; Th2 cytokine

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CLEMASTINE FUMARATE; CS 560; GAMMA INTERFERON; INTERLEUKIN 4; PEMIROLAST; PULLULAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL COUNT; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONJUGATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EFFECTOR CELL; EOSINOPHIL; EOSINOPHILIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MAST CELL; POLLEN ALLERGY; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0035072755     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2001.00200.x     Document Type: Article

References (36)

1. Mechanisms of IgE-mediated hypersensitivity
2. Mediators of immediate hypersensitivity
3. Biology of mast cells and basophils
4. Important factors in the nasal manifestation of allergy
5. Predominant Th2-like bronchoalveolar T-lymphocyte population in a topic asthma
6. Phenotype of cells expressing mRNA for Th2 type (interleukin 4 and interleukin 5) and Th1 type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatics and normal subject controls
7. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects
8. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitics
9. Heterogeneity of mast cells and T cells in the nasal mucosa
10. Fluctuations of the number of CD-1 (T6) positive dendritic cells, presumably Langerhan's cells, in the nasal mucosa of patients with an isolated grass pollen allergy before, during and after the grass pollen season
11. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: A biopsy study
12. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells
13. Prophylactic inoculation against hay fever
14. Further observation on the treatment of hay fever by hypodermic inoculation of pollen vaccine
15. Specific immunotherapy in asthma
16. Immunotherapy for nasal allergy
17. Usefulness of immunotherapy with severe summer hay fever uncontrolled by anti-allergic drugs
18. Differences in clinical and immunological reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double blind placebo controlled, specific immunotheray with standardized extracts
19. Seasonal asthma in northern California: Allergic causes and efficacy of immunotherapy
20. Generation of antigen specific suppressor cells during allergy sensitization
21. Changes in nasal metachromatic cells during allergen immunotherapy
22. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the FcεRI, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells
23. Functional expression of the FcεRl in human platelets and in human megakaryocytes
24. Effects of beclomethasone diproprionate nasal spray on subjective and objective findings in perennial allergic rhinitis
25. A clinical evaluation of N′-5 with perennial-type allergic rhinitis. A test by multi-ethnic, intergroup, double-blind comparative method
26. Clinical classification of allergic rhinitis
27. Regulation of cytokine production by sugi allergen-pullulan conjugate
28. Modifications in the TCR contact residue of an antigen
29. Comparison of the in vivo and in vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis
30. Suppression of late phase skin reactions by immunotherapy with ragweed extract
31. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late phase cutaneous responses
32. Responses to ragweed pollen nasal challenge before and after immunotherapy
33. IgE-FcεRI-Mast cell axis in the allergic cycle
34. Effect of IFN-γ on FcεRI mediated cytokine secretion from cultured human mast cells
35. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy
36. Ten year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis